Pfizer gets fresh cancer drug rejection from NICE
LONDON (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.
The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.
(Reporting by Ben Hirschler; Editing by David Cowell)
- Tweet this
- Share this
- Digg this
- Yanukovich backs Ukraine compromise talks as tensions rise
- Chinese hackers spied on Europeans before G20 meeting - researcher
- U.S. Korean War veteran released by North says made 'confession' under duress
- U.S. exits GM stake in $10 billon loss for taxpayers |
- Putin dissolves state news agency, tightens grip on media